Investigational drug · Phase 2
Mocaciclib
Also called: Q901
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Cancer, Metastatic Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Mocaciclib"
First trial start
2022
Aug 30, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Mocaciclib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Cancer
- Metastatic Cancer
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Mocaciclib" as an intervention, largest first.
Qurient Co., Ltd.Industry
NCT05394103 · 130 participants (planned) · Start Aug 30, 2022 · Primary completion Mar 31, 2029
Drug: Mocaciclib (Q901); KEYTRUDA® (pembrolizumab) and 1 more · For: Advanced Cancer; Metastatic Cancer
Sites: Phoenix, Arizona; Los Angeles, California; Jacksonville, Florida · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition.
Jung H, Lee Y, Yu D, et al. · Sci Adv 2026
- Sensitizing tumor response to topoisomerase I antibody drug conjugate by selective CDK7 inhibition.
Jung H, Lee Y, Yu D, et al. · bioRxiv 2025
Also in development for Advanced Cancer
- ObrixtamigBI 764532Phase 36 trials
Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
- EzabenlimabBI 754091Phase 32 trials
Boehringer Ingelheim · Advanced Cancer, Neoplasm Metastasis, Advanced Tumors
- ALK201Phase 22 trials
Shanghai Allink Biotherapeutics Co., Ltd. · NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Cancer, Advanced Solid Tumors
- CVM-1118TRX-818Phase 22 trials
TaiRx, Inc. · Hepatocellular Carcinoma, Advanced Cancer, Neuroendocrine Tumors
- KB707Phase 22 trials
Krystal Biotech, Inc. · Cancer, Melanoma Stage III, Melanoma Stage IV
- LY188011Phase 22 trials
Eli Lilly · Neoplasms, Child, Adolescent
- Personalized Neoantigen Peptide VaccinePhase 22 trials
Seqker Biosciences, Inc. · Solid Tumors, Advanced Cancer, Recurrent Cancer
- TST001Phase 22 trials
Transcenta Therapeutics (Hangzhou) Co., Ltd. · Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.